Sex: F
Vaccine: COVID19, COVID19, COVID19, VARZOS
Symptoms: COVID-19, Erythema
Clinical narrative: vaccines have been difficult; COVID (minor); developed a large red spot not at the injection site; This non-serious case was reported by a other health professional and described the occurrence of localized erythema in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included covid-19 vaccine for an unknown indication, covid-19 vaccine for an unknown indication and covid-19 vaccine (Covid-19 Booster) for an unknown indication.   Previously administered products included NSAIDS (received on an unknown date).   On an unknown date, the patient received the 1st dose of Shingrix, covid-19 vaccine, covid-19 vaccine and Covid-19 Booster. On an unknown date, an unknown time after receiving Shingrix, the patient experienced localized erythema (Verbatim: developed a large red spot not at the injection site), feeling bad (Verbatim: vaccines have been difficult) and covid-19 (Verbatim: COVID (minor)). The patient was treated with ace inhibitor nos (Ace Inhibitor). The outcome of the localized erythema was recovered/resolved (duration 1 week) and the outcome of the feeling bad and covid-19 were unknown.   The reporter considered the localized erythema to be related to Shingrix. It was unknown if the reporter considered the feeling bad and covid-19 to be related to Shingrix.     The company considered the localized erythema to be related to Shingrix. It was unknown if the company considered the feeling bad and covid-19 to be related to Shingrix.   Linked case(s) involving the same patient:  US2020AMR053969   Additional Information: Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication.  The patient experianced large red spot after every shigrix vaccination . The large red spot not at the site of administration but red spot at few inches from site of administration.  The patient was fine but think about red spot which are not at site of administration. The reporter consented to follow up.   Follow up information was received from the other healthcare professional on 4th March 2020: The patient's demographic details were updated. The patient received the 1st dose of Shingrix and experienced localized erythema.  The patient was treated with ace inhibitor nos (Ace Inhibitor). The outcome of the localized erythema was resolved.  The reporter considered the localized erythema to be related to Shingrix. The VAERS details were updated.  Follow-up information received on 28-Feb-2023 This case US2020AMR014835 would be deleted. Reason for deletion- Reason for case deletion: As per the follow-up report of 28th Feb 2023, it was confirm that the patient got 2 shingrix vaccine and continued to have small breakouts of shingles, according to that only single case need to keep as valid along with shingles and all the information of case (US2020AMR014835) would be merge in the case and all the future correspondence would be added in case US2020AMR053969, which stands as case of records.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR053969:same reporter - 1st dose case